Michelle T. Muldong

Hypoxia-Induced PIM Kinase and Laminin-Activated Integrin α6 Mediate Resistance to PI3K Inhibitors in Bone-Metastatic CRPC

D. Durden, E. Corey, R. Toth, 2019, bioRxiv.

Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer

K. Messer, M. Karin, C. Kane, 2020, Journal of Translational Medicine.

Tumor infiltrating B-cells are increased in prostate cancer tissue

M. Karin, C. Kane, A. Shabaik, 2014, Journal of Translational Medicine.

Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancer

C. Kane, R. Sah, K. Masuda, 2016, Asian journal of urology.

A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand

Chan Hyuk Kim, P. Schultz, C. Kane, 2021, Science Advances.

Novel Dormancy Mechanism of Castration Resistance in Bone Metastatic Prostate Cancer Organoids

T. Gaasterland, C. Kane, C. Jamieson, 2022, International journal of molecular sciences.

PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche

N. Cacalano, Wenxue Ma, M. Liss, 2014, Journal of Translational Medicine.